Jan 28, 2021 10:45pm Johnson & Johnson is seeking a nod for amivantamab as a second-line treatment for lung cancer patients with a rare EGFR mutation, but the company is already working on moving the candidate into the front-line setting. (Janssen)
Johnson & Johnson’s EGFR-MET bispecific antibody is padding its case ahead of a potential FDA nod. The drug shrank tumors in 40% of lung cancer patients with a rare EGFR mutation and curbed tumor growth in nearly three-quarters of patients.
The phase 2 data, presented virtually at the World Conference on Lung Cancer (WCLC), come from 81 patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The patients’ cancer had spread beyond the lungs or couldn’t be treated with surgery and had gotten worse despite taking platinum chemotherapy.
Janssen: New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
FOR EU TRADE AND MEDICAL MEDIA ONLY Not for distribution in the UK and Benelux
The Janssen Pharmaceutical Companies of Johnson Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.
1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings showed robust activity and durable responses with a tolerable and manageable safety profile (Abstract #3031) in patients with NSCL
Workers in the Biond Biologics lab in Misgav, Israel (Courtesy)
The anti-cancer drug developed by Biond Biologics, which the Israeli startup will now try on humans in clinical trials with France-based multinational Sanofi, takes a multipronged approach to fighting tumors, activating three kind of cells in the immune system at the same time.
Paris-based multinational pharma firm Sanofi signed a licensing agreement earlier this month for Biond’s flagship anti-tumor drug BND-22, a cancer immunotherapy medication.
Under the terms of the agreement, Biond will receive an upfront payment of $125 million in cash and up to $1 billion in potential development, regulatory and sales milestones, as well as tiered double-digit royalty payments, the Israeli firm said in a statement. Biond will lead the first-in-human Phase 1a clinical trial of the drug, evaluating its safety and tolerability. Afterwards, Sanofi will take on development responsibilities and commercialization of the drug, Biond
Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
SurvivorNet Teams with NYU Langone Health for Close the Gap, an Expansive Media Vertical Devoted to Racial Inequities in Cancer
The health media platform s major new effort to provide stories and information that help close the racial gap in cancer care is backed by the experts at NYU Langone s Perlmutter Cancer Center.
News provided by
Share this article
NEW YORK, Jan. 14, 2021 /PRNewswire/
SurvivorNet, the nation s leading media company for cancer information, is announcing a collaboration with NYU Langone Health s Perlmutter Cancer Center for
SurvivorNet.com devoted exclusively to telling patient stories, providing expert medical counsel, and delivering vetted health information as it relates to the huge disparities that exist for racial minorities in healthcare, particularly when it comes to cancer.